|
【结 构 式】 
|
【分子编号】21228 【品名】7-(2-[(2S,4S)-4-[(9-fluoro-3,3,6-trimethylhexahydro-2H,6H-pyrano[3,4-b][1,4]dioxepin-8-yl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-naphthacenyl]-2-oxoethoxy)-7-oxoheptanoic acid 【CA登记号】 |
【 分 子 式 】C39H45FO15 【 分 子 量 】772.7757032 【元素组成】C 60.62% H 5.87% F 2.46% O 31.06% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号：(XIV)The condensation of (XII) with monosodium pimelate (XIII) in acetone - water yields the protected hemipimelate (XIV), which is finally treated with hot acetic acid - water.
| 【1】 Umezawa, H.; Umezawa, S.; Tsuchiya, T.; Takeuchi, T.; Takagi, Y.; Yoneda, T.; Fukatsu, S. (Microbial Chemistry Research Foundation); Novel anthracycline derivs., a process for preparing them and their use as medicaments. EP 0275431; JP 1988141992 . |
| 【2】 Tsuchiya, T.; Takagi, Y.; Umezawa, S.; Takeuchi, T.; Komuro, K.; Nosaka, C.; Umezawa, H.; Fukatsu, S.; Yoneta, T.; Synthesis and antitumor activities of 14-O-acyl derivatives of 7-O-(2, 6-dideoxy-2-fluoro-alpha-L-talopyranosyl)adriamycin. J Antibiot 1988, 41, 7, 988-91. |
| 【3】 Hoshi, A.; Prous, J.; Castaner, J.; ME2303. Drugs Fut 1989, 14, 8, 756. |
| 【4】 Omoto, S.; Kondo, S.; Fukatsu, S.; Takeuchi, T.; Umezawa, K.; Tsuchiya, T.; Umezawa, S.; Biological properties of ME2303 (FAD-104), a new anthracycline. Drug Exp Clin Res 1988, 14, 7, 435-9. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XII) | 21226 | (8R,10S)-8-(2-bromoacetyl)-10-[(9-fluoro-3,3,6-trimethylhexahydro-2H,6H-pyrano[3,4-b][1,4]dioxepin-8-yl)oxy]-6,11-dihydroxy-1-methoxy-7,8,9,10-tetrahydro-5,12-naphthacenedione | C32H34BrFO10 | 详情 | 详情 | |
| (XIII) | 21227 | sodium 6-carboxyhexanoate | C7H11NaO4 | 详情 | 详情 | |
| (XIV) | 21228 | 7-(2-[(2S,4S)-4-[(9-fluoro-3,3,6-trimethylhexahydro-2H,6H-pyrano[3,4-b][1,4]dioxepin-8-yl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-naphthacenyl]-2-oxoethoxy)-7-oxoheptanoic acid | C39H45FO15 | 详情 | 详情 |
Extended Information